Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921114 · ClinicalTrials.gov registry record · NA
The PROOF Study: The PICC Related Obstruction Of Flow Study
A NA study, sponsored by Angiodynamics.
- Terminated
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT01921114 is a NA study that was terminated before completion, run by Angiodynamics. The registered enrollment target is 57 participants.
The verdict
NCT01921114, a NA study, was terminated before completion, sponsored by Angiodynamics.
- TERMINATED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
The main purpose of this study is to confirm whether the AngioDynamics BioFlo™ Peripherally Inserted Central Catheter (PICC) is associated with less formation of blood clots compared to another commercially available PICC.
Interventions
- DEVICE BioFlo™ Peripherally Inserted Central Catheter (PICC)
- DEVICE Bard® Dual-Lumen PowerPICC SOLO2®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01921114
The ClinicalTrials.gov registry entry for NCT01921114 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiodynamics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BioFlo™ Peripherally Inserted Central Catheter (PICC) is the first listed.
NCT01921114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01921114 about?
NCT01921114 is a clinical study titled "The PROOF Study: The PICC Related Obstruction Of Flow Study". The main purpose of this study is to confirm whether the AngioDynamics BioFlo™ Peripherally Inserted Central Catheter (PICC) is associated with less formation of blood clots compared to another commercially available PICC.
What is the current status of trial NCT01921114?
This trial is currently terminated. It is a NA study. The enrollment target is 57 participants. The study started on 2013-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01921114?
The interventions under investigation include: BioFlo™ Peripherally Inserted Central Catheter (PICC) (DEVICE), Bard® Dual-Lumen PowerPICC SOLO2® (DEVICE).
Who is sponsoring clinical trial NCT01921114?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.